Ovarian cancer genetics: comparing platinum response groups
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at genetic and other factors that may explain why some people with ovarian cancer respond well to platinum-based chemotherapy for many years, while others do not respond at all. The goal is to better understand these differences to improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older) receiving care at the Jean Perrin Center in France.
- You have ovarian cancer at any stage and have received platinum-based chemotherapy as your first treatment.
- You either had the cancer get worse during or right after the first platinum treatment (refractory group), OR you have not had the cancer come back for at least 5 years after finishing that treatment (long-term responder group).
- You agree to have your genetic information studied and sign a consent form.
- You are covered by French social security or equivalent health coverage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for new ways to treat ovarian cancer that has become resistant to current therapies. By joining, you may help researchers develop better treatment options for women like you.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
This trial is a pre-screening process for people with ovarian cancer whose disease came back quickly after platinum chemotherapy (or who cannot take platinum). It may help match you to future study options using a tumor tissue sample.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.